News & press releases

< Back to News & Press Releases

Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

November 23, 2022 8:00 AM
Download Pdf

Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium


NEWARK, Calif., November 23, 2022 (GLOBENEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.


Presentation Title:                  Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan

Authors:                                     Francois-Clement Bidard, Diana Bello Roufai, Arielle J. Medford, Vijaya Tirunagaru,  Robert C. Doebele, Aditya Bardia

Poster Session/ Category:   Session 6 / Treatment: Therapeutic Strategies – Novel Targets and Targeted Agents              

Poster Number:                       P6-10-10

Session Date and Time:       Friday, December 9, 2022; 7:00 AM CT

Location:                                 Henry B. Gonzalez Convention Center, Hall 1


A copy of the presentation material scan be accessed by visiting the "Resources” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.


About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.


Investor Contact

Dan Ferry

LifeSci Advisors



Media Contact

Jordyn Temperato

LifeSci Communications